Associated Papers
Nucleotide Substitution Biases in Related Cancer Driver Genes.
Khadre A et al.
International Journal of Molecular Sciences, 2025
A Phase I/II Trial of Ruxolitinib with Chemotherapy for Patients with Relapsed and/or Refractory Philadelphia-like Acute Lymphoblastic Leukemia.
Goulart H et al.
Clinical Lymphoma, Myeloma & Leukemia, 2025
Structural Analysis of Janus Tyrosine Kinase Variants in Hematological Malignancies: Implications for Drug Development and Opportunities for Novel Therapeutic Strategies.
Rodriguez Moncivais OJ et al.
International Journal of Molecular Sciences, 2023
Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches.
Nair PC et al.
Blood Cancer Discovery, 2023
Clinical features and prognosis of pediatric acute lymphocytic leukemia with JAK-STAT pathway genetic abnormalities: a case series.
Hu M et al.
Annals of Hematology, 2023
New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation.
Arwood ML et al.
Cell Chemical Biology, 2023
RaScALL: Rapid (Ra) screening (Sc) of RNA-seq data for prognostically significant genomic alterations in acute lymphoblastic leukaemia (ALL).
Rehn J et al.
Plos Genetics, 2022
Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing.
Newman S et al.
Cancer Discovery, 2021
Comprehensive Custom NGS Panel Validation for the Improvement of the Stratification of B-Acute Lymphoblastic Leukemia Patients.
Montaño A et al.
Journal of Personalized Medicine, 2020
JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias.
Kim SK et al.
Genes & Development, 2018
Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia.
Zhang Q et al.
Oncotarget, 2018
A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH.
Sadras T et al.
Cancer Genetics, 2017
Genomic and transcriptional landscape of P2RY8-CRLF2-positive childhood acute lymphoblastic leukemia.
Vesely C et al.
Leukemia, 2017
CRLF2-Positive B-Cell Acute Lymphoblastic Leukemia in Adult Patients: A Single-Institution Experience.
Konoplev S et al.
American Journal of Clinical Pathology, 2017
Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes.
Messina M et al.
Oncotarget, 2016
Effects of the I682F mutation on JAK2's activity, structure and stability.
Li F et al.
International Journal of Biological Macromolecules, 2015
The molecular regulation of Janus kinase (JAK) activation.
Babon JJ et al.
The Biochemical Journal, 2014
Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase.
Shan Y et al.
Nature Structural & Molecular Biology, 2014
Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses.
Varghese LN et al.
The Biochemical Journal, 2014
Lymphoid malignancies: Another face to the Janus kinases.
Scott LM
Blood Reviews, 2013
Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.
Harvey RC et al.
Blood, 2010
Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia.
Russell LJ et al.
Blood, 2009
JAK mutations in high-risk childhood acute lymphoblastic leukemia.
Mullighan CG et al.
Proceedings of the National Academy of Sciences of the United States of America, 2009